암 유전자 패널 및 프로파일링 시장 : 암별, 용도별, 조직별, 유전자 유형별, 잠재 시장 규모 - 경영진 및 컨설턴트 가이드 포함(2025-2029년)

Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size. With Executive and Consultant Guides 2025-2029

US $ 6,995 ￦ 10,121,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,185,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,249,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

암 유전자 패널 및 유전체 프로파일링은 암 진단과 치료를 빠르게 변화시키고 있습니다. 그리고 이제 인공지능이 새로운 문을 열고 있습니다. 암 전문의들이 암과 관련된 수백 개의 유전자 정보를 일상적으로 사용하기 시작하면서 시장은 전문적 틈새 시장에서 주류 시장으로 이동하고 있습니다. 시장은 두 개의 서로 다른 부문에서 폭발적으로 성장하고 있습니다.

종합 패널, 유전체 프로파일링, 고위험 유방암 패널. 처음부터 새로 만들어진 시장에서 진입 기업들이 어떻게 포지셔닝을 놓고 경쟁하고 있는지 알아보세요. 그리고 일부 진입 기업은 크게 앞서서 세계로 진출하고 있습니다. 적절한 진단약과 적절한 지원이 프리미엄 가격을 가능하게 하는, 큰 기회가 있는 역동적인 시장 상황입니다. 그리고 과학이 발전함에 따라 새로운 기회가 주기적으로 창출되고 있습니다. 시퀀싱 비용은 계속 하락하고 있습니다.

본 보고서는 세계 암 유전자 패널 및 프로파일링 시장에 대해 조사했으며, 18개국 및 4개 지역의 상세한 분석과 함께 암 유형별, 용도별, 조직별 동향, 시장 진입 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 암 유전자 패널 및 프로파일링이란 무엇인가?
• 시퀀싱 혁명
• 시장 정의
• 조사 방법
• 관점 : 헬스케어비 지출

제3장 시장 개요

• 시장 진출 조직
  • 학술연구기관
  • 진단 시험 개발자
  • 계측 기기 공급업체
  • 화학제품/시약 공급업체
  • 병리 공급업체
  • 독립계 임상 검사실
  • 공공 국립/지역 연구소
  • 병원 검사실
  • 임상 검사실
  • 감사 기관
  • 인증 기관
• 종양 유전체학
• 암 관리와 진단
• 도입 단계 - 향후 전망
• 산업 구조의 영향
• 현재 이용 가능한 대규모 종합적 어세이
• 프로파일링과 전장 엑솜(또는 유전체) 시퀀싱 가격 설정

제4장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측과 자동화
• 진단 기술 개발

제5장 암 패널 및 프로파일의 최근 동향

제6장 주요 기업 개요

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Admera Health, LLC
• Aethlon Medical
• Agilent
• Amoy Diagnostics Co., Ltd.
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• C2i Genomics
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellMax Life
• Cepheid(Danaher)
• Charles River Laboratories
• Circulogene
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• GeneDx Holdings
• GeneFirst Ltd.
• Genetic Technologies Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• KEW
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• OraLiva
• Oxford Nanopore Technologies
• Panagene
• Personalis
• Perthera
• PGDx(Labcorp)
• Precipio
• PrecisionMed
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Revvity
• Roche Diagnostics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Variantyx
• Vela Diagnostics
• Veracyte
• VolitionRX
• Vortex Biosciences

제7장 암 유전자 패널과 프로파일 세계 시장

• 국가별 세계 시장 개요
• 암 유형별 세계 시장 - 개요
• 용도별 세계 시장 - 개요
• 조직별 세계 시장 - 개요
• 세계 시장 생식세포 및 체세포 - 개요

제8장 세계의 암 유전자 패널과 프로파일 시장 - 암 유형별

• 종합적인 패널과 프로파일
• 유방암 유전자 검사
• 대장암 유전자 검사
• 부인과암 유전자 검사
• 혈액암 유전자 검사
• 전립선암 유전자 검사
• 폐암 유전자 검사
• 기타 암 유전자 검사

제9장 세계의 암 유전자 패널과 프로파일 시장 - 용도별

• 임상시험
• 의약품 시험
• 연구 시험

제10장 세계의 암 유전자 패널과 프로파일 시장 - 조직 유형별

• 고형 조직
• 액체 조직 검사

제11장 세계의 암 유전자 검사 시장 - 생식세포계 및 체세포계

• 세계 시장 - 체세포
• 세계 시장 - 생식세포

제12장 잠재적 시장 기회 규모

제13장 부록

ksm

영문 목차

영문목차

OVERVIEW:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. And now Artificial Intelligence is opening new doors. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding in two distinct segments. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Cancer Panel Market - Strategic Situation Analysis
• 1.2. Large Comprehensive Cancer Panel Market - Situation Analysis
• 1.3. Guide for Executives, Marketing, Sales and Business Development Staff
• 1.4. Guide for Management Consultants and Investment Advisors
• 1.5. Impact of Artificial Intelligence on Cancer Profiling Market

2. Introduction and Market Definition

• 2.1. What are Cancer Gene Panels and Profiling?
• 2.2. The Sequencing Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare Spending
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Healthcare and Pharmaceuticals
  • 2.5.3. Spending on Diagnostics
  • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

• 3.1. Players in a Dynamic Market
  • 3.1.1. Academic Research Lab
  • 3.1.2. Diagnostic Test Developer
  • 3.1.3. Instrumentation Supplier
  • 3.1.4. Chemical/Reagent Supplier
  • 3.1.5. Pathology Supplier
  • 3.1.6. Independent Clinical Laboratory
  • 3.1.7. Public National/regional Laboratory
  • 3.1.8. Hospital Laboratory
  • 3.1.9. Physicians Office Lab (POLS)
  • 3.1.10. Audit Body
  • 3.1.11. Certification Body
• 3.2. Oncogenomics
  • 3.2.1. Carcinogenesis
  • 3.2.2. Chromosomes, Genes and Epigenetics
    • 3.2.2.1. Chromosomes
    • 3.2.2.2. Genes
    • 3.2.2.3. Epigenetics
  • 3.2.3. Cancer Genes
  • 3.2.4. Germline vs Somatic
  • 3.2.5. Gene Panels, Single Gene Assays and Multiplexing
  • 3.2.6. Genomic Profiling
  • 3.2.7. The Comprehensive Assay
  • 3.2.8. Changing Clinical Role
  • 3.2.9. The Cancer Screening Market Opportunity
• 3.3. Cancer Management vs. Diagnosis
  • 3.3.1. The Role of Risk Assessment
  • 3.3.2. Diagnosis
  • 3.3.3. Managing
  • 3.3.4. Monitoring
• 3.4. Phases of Adoption - Looking into The Future
• 3.5. Structure of Industry Plays a Part
  • 3.5.1. Hospital Testing Share
  • 3.5.2. Economies of Scale
    • 3.5.2.1. Hospital vs. Central Lab
  • 3.5.3. Physician Office Lab's
  • 3.5.4. Physician's and POCT
• 3.6. Currently Available Large Comprehensive Assays
• 3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
  • 3.7.1. Medicare Profile Pricing
  • 3.7.2. Whole Exome Sequencing

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Level of Care
  • 4.1.2. Companion Dx
  • 4.1.3. Immuno-oncology
  • 4.1.4. Liability
  • 4.1.5. The Aging Effect
• 4.2. Factors Limiting Growth
  • 4.2.1. State of knowledge
  • 4.2.2. Genetic Blizzard
  • 4.2.3. Protocol Resistance
  • 4.2.4. Regulation and coverage
• 4.3. Instrumentation and Automation
  • 4.3.1. Instruments Key to Market Share
  • 4.3.2. Bioinformatics Plays a Role
• 4.4. Diagnostic Technology Development
  • 4.4.1. Next Generation Sequencing Fuels a Revolution
  • 4.4.2. Single Cell Genomics Changes the Picture
  • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
  • 4.4.4. CGES Testing, A Brave New World
  • 4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Foundation Medicine, Fulgent Genetics to Launch Germline Testing
• 5.3. Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
• 5.4. Lucence Assay Gets Coverage for Advanced Solid Tumors
• 5.5. Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
• 5.6. Roche CGP Assay Shows Concordance With Other NGS-Based Assays
• 5.7. Precede Biosciences Emerges From Stealth With $57M
• 5.8. Geneseeq Nabs CE Marks for Cancer Test Kits
• 5.9. Realm IDx Profiling Test Gets National Health Coverage in Japan
• 5.10. Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
• 5.11. Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
• 5.12. Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling
• 5.13. Cota, Genomic Testing Coop Ink Oncology Partnership
• 5.14. Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract
• 5.15. Prenetics' Cancer Profiling Test Receives FDA Clearance
• 5.16. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
• 5.17. Thermo Fisher Introduces Homologous Score for Cancer Profiling
• 5.18. Genomic Test IDs Cancer Cells Early
• 5.19. Caris Life Sciences to Offer Molecular Profiling Services
• 5.20. Geneseeq to Build Lab for Cancer Profiling in Brazil
• 5.21. Genetron Health Adds New Assays to Pipeline
• 5.22. Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
• 5.23. Guardant Health Receives Medicare Coverage for Guardant360 TissueNext(TM) Test
• 5.24. Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
• 5.25. Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
• 5.26. Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
• 5.27. Labcorp, CCORN Partner for Precision Oncology
• 5.28. Dante Labs Acquires Cambridge Cancer Genomics
• 5.29. Celemics, Strand Partner on Integrated Platform for NGS Analysis
• 5.30. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
• 5.31. Burning Rock Revenues Rise
• 5.32. Caris Life Sciences to Expand Liquid Biopsy Testing
• 5.33. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
• 5.34. Intermountain and Myriad Combine Test Offering
• 5.35. Illumina, Geneseeq to Offer Cancer Testing Kits in China
• 5.36. Exact Sciences to Offer End-to-End Cancer Testing
• 5.37. Guardant Health Turns to Tumor Tissue Sequencing
• 5.38. Tempus Inks Oncology Testing Collaboration With Bayer
• 5.39. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
• 5.40. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
• 5.41. Metastatic Cancer Markers Identified in Clinical WGS Study
• 5.42. Stitch Bio Bets on CRISPR Tech
• 5.43. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
• 5.44. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
• 5.45. Progress, Challenges in Liquid Biopsy Reimbursement
• 5.46. Israeli Startup Curesponse Raises $6M
• 5.47. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
• 5.48. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
• 5.49. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
• 5.50. Germline Results Guides Precision Therapy in Advanced Cancer
• 5.51. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
• 5.52. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
• 5.53. Labs Reporting Cancer Risk Mutations from Tumor Testing
• 5.54. Users Begin Integrating Genomics Data for Clinical Decision Support
• 5.55. Fujitsu Improves Efficiency in Cancer Genomic Medicine

6. Profiles of Key Players

• 6.1. 10x Genomics, Inc.
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Adaptive Biotechnologies
• 6.5. Admera Health, LLC
• 6.6. Aethlon Medical
• 6.7. Agilent
• 6.8. Amoy Diagnostics Co., Ltd.
• 6.9. Anchor Dx
• 6.10. ANGLE plc
• 6.11. ARUP Laboratories
• 6.12. AVIVA Systems Biology
• 6.13. Baylor Miraca Genetics Laboratories
• 6.14. Beckman Coulter Diagnostics (Danaher)
• 6.15. Becton, Dickinson and Company
• 6.16. BGI Genomics Co. Ltd
• 6.17. Bioarray Genetics
• 6.18. Biocartis
• 6.19. Biocept, Inc.
• 6.20. Biodesix Inc.
• 6.21. BioFluidica
• 6.22. BioGenex
• 6.23. BioIVT
• 6.24. Biolidics Ltd
• 6.25. bioMerieux Diagnostics
• 6.26. Bioneer Corporation
• 6.27. Bio-Rad Laboratories, Inc
• 6.28. Bio-Reference Laboratories
• 6.29. Bio-Techne
• 6.30. Bioview
• 6.31. Bristol-Myers Squibb
• 6.32. Burning Rock
• 6.33. C2i Genomics
• 6.34. Cardiff Oncology
• 6.35. Caris Molecular Diagnostics
• 6.36. Castle Biosciences, Inc.
• 6.37. Celemics
• 6.38. CellMax Life
• 6.39. Cepheid (Danaher)
• 6.40. Charles River Laboratories
• 6.41. Circulogene
• 6.42. Clearbridge Biomedics
• 6.43. Clinical Genomics
• 6.44. Cytolumina Technologies Corp.
• 6.45. Datar Cancer Genetics Limited
• 6.46. Diagnologix LLC
• 6.47. Diasorin S.p.A.
• 6.48. Element Biosciences
• 6.49. Enzo Biochem
• 6.50. Epic Sciences
• 6.51. Epigenomics AG
• 6.52. Eurofins Scientific
• 6.53. Exact Sciences
• 6.54. Fabric Genomics
• 6.55. Fluxion Biosciences (Cell Microsystems)
• 6.56. Freenome
• 6.57. FUJIFILM Wako Diagnostics
• 6.58. Fujirebio
• 6.59. GeneDx Holdings
• 6.60. GeneFirst Ltd.
• 6.61. Genetic Technologies Ltd.
• 6.62. Genetron Holdings
• 6.63. GenomOncology
• 6.64. GILUPI Nanomedizin
• 6.65. Guardant Health
• 6.66. HansaBiomed
• 6.67. HTG Molecular Diagnostics
• 6.68. iCellate
• 6.69. ICON PLC
• 6.70. Illumina
• 6.71. Incell Dx
• 6.72. Inivata
• 6.73. Invitae Corporation
• 6.74. Invivogen
• 6.75. Invivoscribe
• 6.76. J&J Innovative Medicine
• 6.77. KEW
• 6.78. Lucence Health
• 6.79. Lunglife AI Inc
• 6.80. MDNA Life SCIENCES, Inc.
• 6.81. MDx Health
• 6.82. Menarini Silicon Biosystems
• 6.83. Mesa Laboratories, Inc.
• 6.84. Millipore Sigma
• 6.85. Miltenyi Biotec
• 6.86. miR Scientific
• 6.87. Myriad Genetics
• 6.88. Nanostring
• 6.89. NantHealth, Inc.
• 6.90. Natera
• 6.91. NeoGenomics
• 6.92. NGeneBio
• 6.93. Novogene
• 6.94. Oncimmune
• 6.95. Oncocyte
• 6.96. OncoDNA
• 6.97. OraLiva
• 6.98. Oxford Nanopore Technologies
• 6.99. Panagene
• 6.100. Personalis
• 6.101. Perthera
• 6.102. PGDx (Labcorp)
• 6.103. Precipio
• 6.104. PrecisionMed
• 6.105. Predictive Oncology
• 6.106. Prenetics
• 6.107. Promega
• 6.108. Qiagen
• 6.109. QuidelOrtho
• 6.110. Rarecells SAS
• 6.111. RareCyte
• 6.112. Revvity
• 6.113. Roche Diagnostics
• 6.114. Screencell
• 6.115. Sherlock Biosciences
• 6.116. Siemens Healthineers
• 6.117. simfo GmbH
• 6.118. Singlera Genomics Inc.
• 6.119. Singular Genomics
• 6.120. Singulomics
• 6.121. SkylineDx
• 6.122. Standard BioTools
• 6.123. Stilla Technologies
• 6.124. Sysmex Inostics
• 6.125. Tempus Labs, Inc.
• 6.126. Thermo Fisher Scientific
• 6.127. Todos Medical
• 6.128. Ultima Genomics
• 6.129. Variantyx
• 6.130. Vela Diagnostics
• 6.131. Veracyte
• 6.132. VolitionRX
• 6.133. Vortex Biosciences

7. The Global Market for Cancer Gene Panels and Profiles

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer Type - Overview
  • 7.2.1. Table - Global Market by Cancer Type
  • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Cancer Type - Base Year
  • 7.2.4. Chart - Global Market by Cancer Type - Final Year
  • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
• 7.3. Global Market by Application - Overview
  • 7.3.1. Table - Global Market by Application
  • 7.3.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Application - Base Year
  • 7.3.4. Chart - Global Market by Application - Final Year
  • 7.3.5. Chart - Global Market by Application - Share by Year
  • 7.3.6. Chart - Global Market by Application - Segment Growth
• 7.4. Global Market by Tissue - Overview
  • 7.4.1. Table - Global Market by Tissue
  • 7.4.2. Chart - Global Market by Tissue - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Tissue - Base Year
  • 7.4.4. Chart - Global Market by Tissue - Final Year
  • 7.4.5. Chart - Global Market by Tissue - Share by Year
  • 7.4.6. Chart - Global Market by Tissue - Segment Growth
• 7.5. Global Market Germline & Somatic - Overview
  • 7.5.1. Table - Global Market Germline & Somatic
  • 7.5.2. Chart - Global Market Germline & Somatic - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market Germline & Somatic - Base Year
  • 7.5.4. Chart - Global Market Germline & Somatic - Final Year
  • 7.5.5. Chart - Global Market Germline & Somatic - Share by Year
  • 7.5.6. Chart - Global Market Germline & Somatic - Segment Growth

8. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

• 8.1. Comprehensive Panels & Profiles
  • 8.1.1. Table Comprehensive Testing - by Country
  • 8.1.2. Chart - Comprehensive Testing Growth
• 8.2. Breast Cancer Gene Testing
  • 8.2.1. Table Breast Cancer Gene Testing - by Country
  • 8.2.2. Chart - Breast Cancer Testing Growth
• 8.3. Colorectal Cancer Gene Testing
  • 8.3.1. Table Colorectal Cancer Gene Testing - by Country
  • 8.3.2. Chart - Colorectal Cancer Gene Testing Growth
• 8.4. Gynecological Cancer Gene Testing
  • 8.4.1. Table Gynecological Cancer Gene Testing - by Country
  • 8.4.2. Chart - Gynecological Cancer Gene Testing Growth
• 8.5. Blood Cancer Gene Testing
  • 8.5.1. Table Blood Cancer Gene Testing - by Country
  • 8.5.2. Chart - Blood Cancer Gene Testing Growth
• 8.6. Prostate Cancer Gene Testing
  • 8.6.1. Table Prostate Cancer Gene Testing - by Country
  • 8.6.2. Chart - Prostate Cancer Testing Growth
• 8.7. Lung Cancer Gene Testing
  • 8.7.1. Table Lung Cancer Gene Testing - by Country
  • 8.7.2. Chart - Lung Cancer Gene Testing Growth
• 8.8. Other Cancer Gene Testing
  • 8.8.1. Table Other Cancer Gene Testing - by Country
  • 8.8.2. Chart - Other Cancer Gene Testing Growth

9. Global Cancer Gene Panels & Profiles Markets - By Type of Application

• 9.1. Clinical Testing
  • 9.1.1. Table Clinical Testing - by Country
  • 9.1.2. Chart - Clinical Testing Growth
• 9.2. Pharmaceutical Testing
  • 9.2.1. Table Pharmaceutical Testing - by Country
  • 9.2.2. Chart - Pharmaceutical Testing Growth
• 9.3. Research Testing
  • 9.3.1. Table Research Testing - by Country
  • 9.3.2. Chart - Research Testing Growth

10. Global Cancer Gene Panels & Profiles Markets - By Tissue Type

• 10.1. Solid Tissue
  • 10.1.1. Table Solid Tissue Testing - by Country
  • 10.1.2. Chart - Solid Tissue Testing Growth
• 10.2. Liquid Tissue Testing
  • 10.2.1. Table Liquid Tissue Testing - by Country
  • 10.2.2. Chart - Liquid Tissue Testing Growth

11. Global Cancer Gene Testing Markets - Germline and Somatic

• 11.1. Global Market Somatic
  • 11.1.1. Table Somatic - by Country
  • 11.1.2. Chart - Somatic Testing Growth
• 11.2. Global Market Germline
  • 11.2.1. Table Germline - by Country
  • 11.2.2. Chart - Germline Testing Growth

12. Potential Market Opportunity Sizes

• 12.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
• 12.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
• 12.3. Potential Market Size - Cancer Diagnosis
• 12.4. Potential Market Size - Therapy Selection

13. Appendices

• 13.1. Growth of Approved IVD Test Menu
• 13.2. Growth of Approved Average IVD Test Fee
• 13.3. The Most Used IVD Assays
• 13.4. The Highest Grossing Assays
• 13.5. Laboratory Fees Schedule

관련자료